Organicell Regenerative Medicine Email Format
Biotechnology ResearchFlorida, United States11-50 Employees
Organicell Regenerative Medicine is a clinical-stage biopharmaceutical company based in Fort Lauderdale, South Florida, focused on developing regenerative biologic therapies for chronic diseases. Its products are derived from perinatal sources and manufactured to retain exosomes, hyaluronic acid, and proteins without adding other substances. The company also offers related services to support its development programs. Its target market includes clinicians and research partners pursuing regenerative therapies within the biotechnology sector. In 2023, Organicell announced leadership appointments—naming Harry Leider as CEO and Howard L. Golub as EVP and CSO—and it continues to develop Zofin, an acellular biologic derived from perinatal sources.